New obesity drug TLC-6740 enters early human testing
NCT ID NCT05822544
First seen Dec 18, 2025 · Last updated May 15, 2026 · Updated 23 times
Summary
This early-stage study tests a new drug called TLC-6740 in healthy volunteers and people with obesity, with or without type 2 diabetes. The main goals are to check safety, how the drug moves through the body, and early signs of effectiveness. Up to 564 participants will take single or multiple doses to gather this information.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
OrsoBio Auckland Research Site 1
RECRUITINGAuckland, New Zealand
-
OrsoBio Auckland Research Site 2
RECRUITINGAuckland, New Zealand
-
OrsoBio Auckland Research Site 3
RECRUITINGAuckland, New Zealand
-
OrsoBio Research Site
RECRUITINGChristchurch, New Zealand
Conditions
Explore the condition pages connected to this study.